lorlatinib — CareFirst (Caremark)

Initial criteria

• Diagnosis of ALK-positive Erdheim-Chester disease
• Used as a single agent

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months